ABEONA THERAPEUTICS INC. Cash Flow Statement
ABEO|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
ABEONA THERAPEUTICS INC. used $76M in operating cash flow and negative free cash flow of $84M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.42 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $71.2M | -$54.2M | -$39.7M | -$84.9M | -$84.2M | -$76.3M | -$27.3M | -$56.7M | -$27.3M | -$14.5M | -$26.8M | -$26.8M | -$10.5M | -$2.5M | -$7.5M |
| Depreciation & Amortization | $2.5M | $2.3M | $3.1M | $3.3M | $4.6M | $7.8M | $741.0K | $2.4M | $741.0K | $551.0K | $11.0K | $11.0K | $419.0K | $233.0K | $238.0K |
| Operating Cash Flow | -$76.3M | -$37.0M | -$43.5M | -$65.7M | -$35.0M | -$62.8M | -$22.7M | -$39.1M | -$22.7M | -$10.4M | -$1.6M | -$1.6M | -$4.0M | -$7.6M | -$6.9M |
| Capital Expenditures | $8.0M | $331.0K | $130.0K | $4.2M | $1.3M | $6.3M | $860.0K | $9.2M | $860.0K | $308.0K | $0 | $0 | $13.0K | $40.0K | $7.0K |
| Free Cash Flow | -$84.3M | -$37.3M | -$43.6M | -$69.8M | -$36.4M | -$69.1M | -$23.5M | -$48.4M | -$23.5M | -$10.7M | -$1.6M | -$1.6M | -$4.0M | -$7.6M | -$6.9M |
| FCF Margin | -1448.5% | -1066.9% | -3084.4% | -2327.2% | -363.6% | -691.3% | -2809.4% | -1612.9% | -2809.4% | -1031.8% | -174.2% | -174.2% | -90.1% | -415.9% | -1427.7% |